Aspergillus fumigatus Cross-Resistance between Clinical and Demethylase Inhibitor Azole Drugs-Reference-Cited by-同舟云学术

Aspergillus fumigatus Cross-Resistance between Clinical and Demethylase Inhibitor Azole Drugs

Published:2021-02-12 Issue:5 Volume:87 Page:
ISSN:0099-2240
Container-title:Applied and Environmental Microbiology
language:en
Short-container-title:Appl Environ Microbiol

Author:

Garcia-Rubio Rocio¹^ORCID,Gonzalez-Jimenez Irene¹,Lucio Jose¹,Mellado Emilia¹²^ORCID

Affiliation:

1. Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain

2. Spanish Network for Research in Infectious Diseases (REIPI RD16/CIII/0004/0003), ISCIII, Majadahonda, Madrid, Spain

Abstract

Due to the worldwide emergence of A. fumigatus azole resistance, this opportunistic pathogen poses a serious health threat, and therefore, it has been included in the watch list in the CDC publication Antibiotic Resistance Threats in the United States, 2019 (CDC, 2019). Azoles play a critical role in the control and management of fungal diseases, not only in the clinical setting but also in agriculture.

Funder

MEC | Instituto de Salud Carlos III

Ministerio de Economía, Industria y Competitividad, Gobierno de España

Publisher

American Society for Microbiology

Subject

Ecology,Applied Microbiology and Biotechnology,Food Science,Biotechnology

Link

https://journals.asm.org/doi/pdf/10.1128/AEM.02539-20

Reference64 articles.

1. Aspergillus fumigatus and Aspergillosis in 2019

2. Triazole Resistance in Aspergillus Species: An Emerging Problem